🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationFDA June 2026 enforcement update — compounding pharmacies Page 16

FDA June 2026 enforcement update — compounding pharmacies

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 366 replies 55,812 viewsPage 16 of 20
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
May 22, 2025 at 12:31 PM#76
Dr.EndoEP said:
It helps to ask what evidence would change your mind before you look at any.

There is a second half to this that has not been said yet. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Last edited: May 22, 2025 at 4:31 PM
5 5MaxMetOK, MounjBrad, nick_newbie and 2 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
May 30, 2025 at 1:56 AM#77

The figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

4 4KristenIndy, MarkLI_maint, Dr.PeteFamMed and 1 other
Reply Quote Save Share Report
MounjBrad
Member
278
890
Oct 2024
Kentucky
Jun 6, 2025 at 3:17 PM#78

A narrower follow-up, since the general answer is now clear:

What did you change at the same time, and can you separate the two now?

3 3nick_SD_fit, ben_calgary, patPC_UT
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jun 14, 2025 at 4:34 AM#79
VendorMark said:
If you are going to change something, change one thing and give it long enough to express itself.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

Last edited: Jun 14, 2025 at 9:34 AM
2 2Dr.SurgeonPGH, rachel_ABQ
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Jun 21, 2025 at 5:46 PM#80
VendorMark said:
If you are going to change something, change one thing and give it long enough to express itself.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

Last edited: Jun 21, 2025 at 6:46 PM
30 5carl_compliance, DanielChem_CHI, marco_milano and 27 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register